Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Charles Schwab Investment Management Inc. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 13.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 379,650 shares of the company’s stock after purchasing an additional 46,375 shares during the period. Charles Schwab Investment Management Inc. owned 0.74% of Spyre Therapeutics worth $8,838,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SYRE. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Spyre Therapeutics in the fourth quarter valued at about $46,000. Quest Partners LLC increased its stake in shares of Spyre Therapeutics by 271.2% in the third quarter. Quest Partners LLC now owns 5,654 shares of the company’s stock valued at $166,000 after buying an additional 4,131 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Spyre Therapeutics in the third quarter valued at about $246,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Spyre Therapeutics in the fourth quarter valued at about $290,000. Finally, MetLife Investment Management LLC increased its stake in shares of Spyre Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 20,132 shares of the company’s stock valued at $592,000 after buying an additional 11,344 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analyst Weigh In

SYRE has been the subject of several recent research reports. Wolfe Research initiated coverage on Spyre Therapeutics in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 price target for the company. The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush reissued an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $50.86.

Spyre Therapeutics Price Performance

Shares of Spyre Therapeutics stock opened at $18.17 on Friday. Spyre Therapeutics, Inc. has a one year low of $17.24 and a one year high of $43.00. The stock’s 50-day moving average is $20.85 and its 200 day moving average is $25.94. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -2.43 and a beta of 2.98.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, sell-side analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).